Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Status:
Enrolling by invitation
Trial end date:
2024-10-28
Target enrollment:
Participant gender:
Summary
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in
attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated
peripheral neuropathy and improving cognitive impairment in patients with breast cancer.
This study will be a randomized placebo controlled parallel study. The study will be
performed in accordance with the ethical standards of Helsinki declaration in 1964 and its
later amendments.
Group one: (Placebo group; n=28) which will receive four cycles of AC regimen (doxorubicin
and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel
(each cycle was given in a weekly basis) plus placebo tablets once daily.
Group two: (Silymarin group; n=28) which will receive the same regimen plus silymarin 140mg
once daily